Findings from a recent phase 3b/4 study of upadacitinib support a treat-to-target strategy for dose escalation or reduction ...

In this video, Robert J. Smith, MD, discusses the many treatment options available to patients with atopic dermatitis.

Apogee Therapeutics’ anti-IL-13 antibody has been tied to a 71% reduction in eczema severity after 16 weeks, hitting the main ...

In this video, Jeff Yu, MD, MS, emphasized the importance of chronic hand eczema awareness and highlighted a study on the causes and treatments of the disease, presented at the Revolutionizing Atopic ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

The antibody treatment could compete with Sanofi’s Dupixent and Eli Lilly’s Ebgylss, while offering the potential for less ...

Any physical activity can be beneficial for eczema, as long as you’re choosing the right clothing and practicing good habits ...

Apogee's APG777 showed a 71% drop in eczema severity and strong itch relief in a Phase 2 trial for atopic dermatitis. Part B ...

According to a recent meta-analysis published in eClinicalMedicine, antibiotic use during pregnancy or in early childhood ...